Nanexa publishes interim report for January – June 2022
The pilot plant inaugurated and GMP certified, patent approved in Europe and product projects approaching clinical phase
Significant events during the second quarter2022
- The European Patent Office (EPO) granted the Nanexa’s patent application relating to the drug delivery system PharmaShell®. The patent protection covers the manufacturing method of PharmaShell and products produced using the method.
- Nanexa was granted funding under the VINNOVA project “Verification in Test Center, Part III” for a maximum amount of SEK 290,000, for an internal research project with the aim of coating monoclonal antibodies (mAbs) with PharmaShell®.
- Nanexa completed its new facilities with offices, R&D laboratory and production pilot plant at Uppsala Business Park and an inauguration ceremony was held in June.
- The Swedish Medical Products Agency made an inspection of Nanexa’s new pilot plant in order to issue a certificate for production and release of clinical trial material. The inspection was made without any major remarks.
- At Nanexa’s Annual General Meeting on June 9, it was decided, among other things, to elect Richard Davis as new board member, on authorizations for the Board to decide on rights issue and directed issue, and to establish a warrant-based incentive program for employees. A total of 983,000 warrants were thereafter subscribed for, corresponding to a maximum dilution of 1.9%.
Significant events after the end of the period
- Nanexa expanded its collaboration agreement with Applied Materials, Inc. through an amendment regulating commercial arrangements, paving the way for potential future license agreements with customers in the pharmaceutical industry.
- Nanexa received extended GMP certificate from the Swedish Medical Products Agency for production and release of clinical trial material in the new pilot plant in Uppsala, based on the inspection made during the second quarter.
Summary of the reporting period 1 April – 30 June 2022
- Turnover amounted to: TSEK 211 (342)
- Operating profit (EBIT) amounted to: TSEK -15,854 (-8,296)
- Profit after tax amounted to: TSEK -16,224 (-8,339)
- Earnings per share amounted to: SEK -0.32 (-0.33)
- Cash flow for the period amounted to: TSEK -20,822 (-6,253)
- Cash and cash equivalents at end of period: TSEK 66,904 (28,596)
Summary of the reporting period 1 January – 30 June 2022
- Turnover amounted to: TSEK 509 (878)
- Operating profit (EBIT) amounted to: TSEK -28,185 (-14,919)
- Profit after tax amounted to: TSEK -28,594 (-15,008)
- Earnings per share amounted to: SEK -0.56 (-0.64)
- Cash flow for the period amounted to: TSEK -38,756 (15,905)
- Cash and cash equivalents at end of period: TSEK 66,904 (28,596)
Figures in brackets refer to the corresponding period in the previous year.
The entire report is available on the company’s website via the following link https://nanexa.com/en/investors/.
Report comment, 26 August at 10:00 am
A live Report comment session will be held at Infront Direkt Studios at 10:00 am, where CEO David Westberg will be answering questions from the reporter and the viewers are given the opportunity post questions via chat.
The webcast is held in Swedish and can be reached via this link.
